This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

NOTE: This dataset has been retired and marked as historical-only.

Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.

Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.

Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).

Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.

Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.

CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.

Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.

Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.

Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.

Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois' National Electronic Disease Surveillance System (I-NEDSS), Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Analysis of ‘COVID vaccination vs. mortality ’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/sinakaraji/covid-vaccination-vs-death on 12 November 2021.

--- Dataset description provided by original source is as follows ---

Context

The COVID-19 outbreak has brought the whole planet to its knees.More over 4.5 million people have died since the writing of this notebook, and the only acceptable way out of the disaster is to vaccinate all parts of society. Despite the fact that the benefits of vaccination have been proved to the world many times, anti-vaccine groups are springing up all over the world. This data set was generated to investigate the impact of coronavirus vaccinations on coronavirus mortality.

Content

country	iso_code	date	total_vaccinations	people_vaccinated	people_fully_vaccinated	New_deaths	population	ratio
country name	iso code for each country	date that this data belong	number of all doses of COVID vaccine usage in that country	number of people who got at least one shot of COVID vaccine	number of people who got full vaccine shots	number of daily new deaths	2021 country population	% of vaccinations in that country at that date = people_vaccinated/population * 100

Data Collection

This dataset is a combination of the following three datasets:

1.https://www.kaggle.com/gpreda/covid-world-vaccination-progress

2.https://covid19.who.int/WHO-COVID-19-global-data.csv

3.https://www.kaggle.com/rsrishav/world-population

you can find more detail about this dataset by reading this notebook:

https://www.kaggle.com/sinakaraji/simple-linear-regression-covid-vaccination

Countries in this dataset:

Afghanistan	Albania	Algeria	Andorra	Angola
Anguilla	Antigua and Barbuda	Argentina	Armenia	Aruba
Australia	Austria	Azerbaijan	Bahamas	Bahrain
Bangladesh	Barbados	Belarus	Belgium	Belize
Benin	Bermuda	Bhutan	Bolivia (Plurinational State of)	Brazil
Bosnia and Herzegovina	Botswana	Brunei Darussalam	Bulgaria	Burkina Faso
Cambodia	Cameroon	Canada	Cabo Verde	Cayman Islands
Central African Republic	Chad	Chile	China	Colombia
Comoros	Cook Islands	Costa Rica	Croatia	Cuba
Curaçao	Cyprus	Denmark	Djibouti	Dominica
Dominican Republic	Ecuador	Egypt	El Salvador	Equatorial Guinea
Estonia	Ethiopia	Falkland Islands (Malvinas)	Fiji	Finland
France	French Polynesia	Gabon	Gambia	Georgia
Germany	Ghana	Gibraltar	Greece	Greenland
Grenada	Guatemala	Guinea	Guinea-Bissau	Guyana
Haiti	Honduras	Hungary	Iceland	India
Indonesia	Iran (Islamic Republic of)	Iraq	Ireland	Isle of Man
Israel	Italy	Jamaica	Japan	Jordan
Kazakhstan	Kenya	Kiribati	Kuwait	Kyrgyzstan
Lao People's Democratic Republic	Latvia	Lebanon	Lesotho	Liberia
Libya	Liechtenstein	Lithuania	Luxembourg	Madagascar
Malawi	Malaysia	Maldives	Mali	Malta
Mauritania	Mauritius	Mexico	Republic of Moldova	Monaco
Mongolia	Montenegro	Montserrat	Morocco	Mozambique
Myanmar	Namibia	Nauru	Nepal	Netherlands
New Caledonia	New Zealand	Nicaragua	Niger	Nigeria
Niue	North Macedonia	Norway	Oman	Pakistan
occupied Palestinian territory, including east Jerusalem
Panama	Papua New Guinea	Paraguay	Peru	Philippines
Poland	Portugal	Qatar	Romania	Russian Federation
Rwanda	Saint Kitts and Nevis	Saint Lucia
Saint Vincent and the Grenadines	Samoa	San Marino	Sao Tome and Principe	Saudi Arabia
Senegal	Serbia	Seychelles	Sierra Leone	Singapore
Slovakia	Slovenia	Solomon Islands	Somalia	South Africa
Republic of Korea	South Sudan	Spain	Sri Lanka	Sudan
Suriname	Sweden	Switzerland	Syrian Arab Republic	Tajikistan
United Republic of Tanzania	Thailand	Togo	Tonga	Trinidad and Tobago
Tunisia	Turkey	Turkmenistan	Turks and Caicos Islands	Tuvalu
Uganda	Ukraine	United Arab Emirates	The United Kingdom	United States of America
Uruguay	Uzbekistan	Vanuatu	Venezuela (Bolivarian Republic of)	Viet Nam
Wallis and Futuna	Yemen	Zambia	Zimbabwe

--- Original source retains full ownership of the source dataset ---

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status.

Click 'More' for important dataset description and footnotes

Dataset and data visualization details:

These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected.

Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type.

** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since the first reported coronavirus case in Washington State on Jan. 21, 2020, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

Description:

This comprehensive dataset provides global information on both COVID-19 related deaths and vaccinations from January 5, 2020, to August 4, 2024. It consists of two parts: one tracking COVID-19 cases, deaths, and population statistics, and another monitoring vaccination progress worldwide. This dataset allows for an in-depth analysis of the pandemic’s spread, fatality rates, and the effectiveness of vaccination campaigns across various countries and regions.

Researchers and data analysts can use this dataset to study trends, compare countries, and evaluate public health responses throughout the COVID-19 pandemic.

Includes:

CovidDeaths Dataset: Records of total cases, deaths, and population.

CovidVaccinations Dataset: Records of daily vaccination counts and cumulative totals.

Use Cases:

Analyzing death rates relative to confirmed cases. Examining the percentage of population affected by COVID-19. Evaluating vaccination rates and coverage across different regions. This dataset is ideal for data exploration, statistical analysis, and visualizations related to the COVID-19 pandemic.

Dataset no longer updated: Due to changes in the collection and availability of data on COVID-19, this dataset is no longer updated. Latest information about COVID-19 is available via the UKHSA data dashboard. The UK government publish daily data, updated weekly, on COVID-19 cases, vaccinations, hospital admissions and deaths. This note provides a summary of the key data for London from this release. Data are published through the UK Coronavirus Dashboard, last updated on 23 March 2023. This update contains: Data on the number of cases identified daily through Pillar 1 and Pillar 2 testing at the national, regional and local authority level Data on the number of people who have been vaccinated against COVID-19 Data on the number of COVID-19 patients in Hospital Data on the number of people who have died within 28 days of a COVID-19 diagnosis Data for London and London boroughs and data disaggregated by age group Data on weekly deaths related to COVID-19, published by the Office for National Statistics and NHS, is also available. Key Points On 23 March 2023 the daily number of people tested positive for COVID-19 in London was reported as 2,775 On 23 March 2023 it was newly reported that 94 people in London died within 28 days of a positive COVID-19 test The total number of COVID-19 cases identified in London to date is 3,146,752 comprising 15.2 percent of the England total of 20,714,868 cases In the most recent week of complete data (12 March 2023 - 18 March 2023) 2,951 new cases were identified in London, a rate of 33 cases per 100,000 population. This compares with 2,883 cases and a rate of 32 for the previous week In England as a whole, 29,426 new cases were identified in the most recent week of data, a rate of 52 cases per 100,000 population. This compares with 26,368 cases and a rate of 47 for the previous week Up to and including 22 March 2023 6,452,895 people in London had received the first dose of a COVID-19 vaccine and 6,068,578 had received two doses Up to and including 22 March 2023 4,435,586 people in London had received either a third vaccine dose or a booster dose On 22 March 2023 there were 1,370 COVID-19 patients in London hospitals. This compares with 1,426 patients on 15 March 2023. On 22 March 2023 there were 70 COVID-19 patients in mechanical ventilation beds in London hospitals. This compares with 72 patients on 15 March 2023. Update: From 1st July updates are weekly From Friday 1 July 2022, this page will be updated weekly rather than daily. This change results from a change to the UK government COVID-19 Dashboard which will move to weekly reporting. Weekly updates will be published every Thursday. Daily data up to the most recent available will continue to be added in each weekly update. Data summary Local authority data Demographics Notes on data sources Source: UK Coronavirus Dashboard. For more information see: Coronavirus (COVID-19) in the UK - About the Data. Cases Data UK Health Security Agency (UKHSA) reports new and cumulative cases identified by Pillar 1 and Pillar 2 testing. Pillar 1 testing relates to tests carried out in UKHSA laboratories or NHS Hospitals for those with clinical need, and health and care workers. Pillar 2 testing relates to tests carried out on the wider population in Lighthouse laboratories, public, private, and academic sector laboratories or using lateral flow devices. The cases data is published by day for Countries within the UK, and Regions, Upper Tier Local Authority (UTLA) and Lower Tier Local Authority (LTLA) within England. The data used here is taken from the regional and UTLA level cases data. Notice: Changes to COVID-19 case reporting As of 31 January 2022, UKHSA moved all COVID-19 case reporting in England to use an episode-based definition which includes possible reinfections. Those testing positive beyond 90 days of a previous infection are now counted as a separate infection episode (a possible reinfection episode). Previously people who tested positive for COVID-19 were only counted once in case numbers published on the daily dashboard, at the date of the first infection. Full details of the changes can be found here Changes to COVID-19 testing in England The availability of free COVID-19 tests in England changed on 1 April 2022. Information on who can access free tests has been published by UKHSA. Changes to patient testing in the NHS in England have also been published by NHS England. Deaths data Data on COVID-19 associated deaths in England are produced by UKHSA from multiple sources linked to confirmed case data. Deaths are only included if the deceased had a positive test for COVID-19 and died within 28 days of the first positive test. Postcode of residence for deaths is collected at the time of testing. This is supplemented, where available, with information from ONS mortality records, Health Protection Team reports and NHS Digital Patient Demographic Service records. Full details of the methodology are available in the technical summary of the PHE data series on deaths in people with COVID-19. Hospital admissions data UKHSA publish the daily total number of patients admitted to hospital, patients in hospital and patients in beds which can deliver mechanical ventilation with COVID-19. In England this includes COVID-19 patients being treated in NHS acute hospitals, mental health and learning disability trusts, and independent service providers commissioned by the NHS. Vaccination data UKHSA publish the number of people who have received a COVID-19 vaccination, by day on which the vaccine was administered. Data are reported daily and can be updated for historical dates as vaccinations given are recorded on the relevant system. Therefore, data for recent dates may be incomplete. Vaccinations that were carried out in England are reported in the National Immunisation Management Service which is the system of record for the vaccination programme in England. Only people aged 12 and over who have an NHS number and are currently alive are included. Age is defined as a person's age at 31 August 2021. The data includes counts of vaccinations by age band, dose, region, and local authority. Additional analysis of the vaccine roll out in London can be found here. ONS population estimates The counts of vaccines given has been converted to percentage of the population vaccinated using the ONS 2020 mid-year population estimates. This is a different population estimate to that used on the UK Coronavirus Dashboard for sub-national data. The UK Coronavirus Dashboard uses people aged 16 and over in the National Immunisation Management Service (NIMS), which is based on GP registrations. In more urban areas like London, NIMS is likely to give an overestimate of the population due to increased population mobility increasing the likelihood duplicate or out of date GP records. Due to the differences in population estimates the percentage of the population vaccinated given here will be higher than the figures included for London on the UK Coronavirus Dashboard. Data and Resources phe_deaths_age_london.csv Source: https://coronavirus.data.gov.uk/ phe_deaths_london_boroughs.csv Source: https://coronavirus.data.gov.uk/ phe_vaccines_age_london_boroughs.csv

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 19 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors.

Currently, CDC provides the public with three versions of COVID-19 case surveillance line-listed data: this 19 data element dataset with geography, a 12 data element public use dataset, and a 33 data element restricted access dataset.

The following apply to the public use datasets and the restricted access dataset:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data are suppressed to protect individual privacy.
• Datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensure that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

COVID-19 Case Reports COVID-19 case reports are routinely submitted to CDC by public health jurisdictions using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19. Current versions of these case definitions are available at: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/. All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for lab-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. States and territories continue to use this form.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.

Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question "Was the individual hospitalized?" where the possible answer choices include "Yes," "No," or "Unknown," the blank value is recoded to "Missing" because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race, ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<11 COVID-19 case records with a given values). Suppression includes low frequency combinations of case month, geographic characteristics (county and state of residence), and demographic characteristics (sex, age group, race, and ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These and other COVID-19 data are available from multiple public locations: COVID Data Tracker; United States COVID-19 Cases and Deaths by State; COVID-19 Vaccination Reporting Data Systems; and COVID-19 Death Data and Resources.

Notes:

March 1, 2022: The "COVID-19 Case Surveillance Public Use Data with Geography" will be updated on a monthly basis.

April 7, 2022: An adjustment was made to CDC’s cleaning algorithm for COVID-19 line level case notification data. An assumption in CDC's algorithm led to misclassifying deaths that were not COVID-19 related. The algorithm has since been revised, and this dataset update reflects corrected individual level information about death status for all cases collected to date.

June 25, 2024: An adjustment

Since 2 April 2021, these files are no longer updated. Their communication will resume, but we are not in a position to give you a precise date to date. ### Vaccination against COVID-19 From the start of the vaccination campaign, the health authorities were provided with information to enable daily monitoring of the progress and deployment of the campaign on the territory. These, collected from institutions for the elderly and vaccination centres, were transmitted by the Regional Health Agencies. At the same time, Health Insurance has developed the Vaccine Covid Information System (VAC-SI), which is now fully operational after an analysis of the completeness and completeness of the data. The Vaccine Covid information system is powered by healthcare professionals carrying out vaccinations. Based on the use of these data, Santé Publique France publishes in open data the vaccine coverage indicators. #### What data? Data from the Vaccine Covid information system allows a near-real-time count (J-1) of the number of people who have been injected with Covid vaccine, taking into account the number of doses received, the vaccine, age, sex and geographical level (national, regional and departmental). The indicators available in open access on this dataset relate to the daily number of people with vaccinated comorbidities by date of injection (as well as this cumulative number), by age group They are declined on a scale: national, regional and departmental. Persons with co-morbidities are identified a priori by Cnam on the basis of the recommendations of the High Health Authority (HAS) for priority persons for COVID-19 Vaccination as identified as confirmed risk of serious form or death. Identification is carried out in particular for persons benefiting from long-term effects (ALD), or by targeting CIM codes. In particular, people with: diabetes, chronic kidney failure, COPD and respiratory failure, high blood pressure, heart failure, solid organ transplantation or allograft of haematopoietic stem cells, obesity, cancer and malignant haematologic diseases undergoing treatment with chemotherapy, some rare diseases (see list on the Ministry of Health website), trisomy 21. Only those for whom the department could be located are shown on the maps. Due to the time frame for entry into Covid Vaccine after vaccination in certain structures, a delay is needed to consolidate the data. **From 07/04/2021, the age of vaccinated persons will be calculated from the date of birth (and not the year of birth only). This implies, within Ehpad/USLS, a slight increase in immunisation coverage among professionals, which is accompanied by a slight decrease in immunisation coverage among residents. Overall, for all Vacsi indicators, this leads to some variations in age distributions. #### Precaution of data use Although the new injections are now seized over the water in Vaccin Covid, some injections since the end of December have not yet been entered in Vaccine Covid. In some regions, the Vaccine Covid data are now more complete than the increase made by the ARS, but in others this is not the case yet — especially in Île de France, Provence Alpes Côte d’Azur and Auvergne Rhône Alpes. The data that will now be published every day by Santé publique France at the date of injection will make it possible to report on this catch-up. In the departmental files, if a line for a number of vaccinated at a given date is missing, it is that there was no vaccination that day in the department. The age classes used are as follows: * 0: All ages * 24: 18-24 * 29: 25-29 * 39: 30-39 * 49: 40-49 * 59: 50-59 * 64: 60-64 The region (column “reg”) follows the codification of the INSEE Official Geographical Code, it is codified as follows: * 01: Guadeloupe * 02: Martinique * 03: Guyana * 04: The Meeting * 11: Ile-de-France * 24: Centre-Val de Loire * 27: Burgundy-Franche-Comté * 28: Normandy * 32: Haute-de-France * 44: Great East * 52: Country of the Loire * 53: Brittany * 75: New-Aquitaine * 76: Occitania * 84: Auvergne-Rhône-Alpes * 93: Provence-Alpes-Côte d’Azur * 94: Corsica

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

For English, see below This file contains: - The cumulative attendance for at least one COVID-19 vaccination and COVID-19 vaccination rate basic series for persons aged 12 years and older (from 4 January 2021) and the cumulative vaccination rate of the repeat vaccination against corona within the autumn round 2022 for people aged 12 and older (from 19 September 2022) by neighbourhood, per calendar week, per birth cohort. The file is structured as follows: - A set of records per district. When the turnout or vaccination rate is less than or equal to 5% or greater than or equal to 95%, these are shown as “<=5” or “>=95” respectively due to possible traceability. When less than 60 people live in more than one district in a municipality, the number of vaccinations in that district are not shown due to possible traceability and 9999 is displayed (censorship). If one district in a municipality has to be censored due to low population numbers, then it has been merged with a neighboring district based on ID-matching code, so that the columns population, 'Coverage_primary_partly','Coverage_primary_completed' and 'Coverage_repeat_vaccination_autumn_round' of both districts have been merged . Based on these numbers, the vaccination attendance and vaccination coverage were calculated per district (per district denominator data Population_merged). This file is updated every four weeks on a Tuesday with data from the previous four weeks up to and including the last Sunday before the update. Origin of the data: Numerator: Vaccinations registered in CIMS (COVID Vaccination Information and Monitoring System) (https://www.rivm.nl/covid-19-vaccinatie/privacy), performed by the GGDs, general practitioners and others performers. CIMS data only includes data from vaccinations if the vaccinee has given permission for their vaccination(s) to be centrally registered in CIMS. Persons who have died or emigrated are removed from the counter. Denominator: Number of residents aged 12 and older (born in 2010 or before) by district (Basisregister personal data). The denominator is updated once per quarter. The version number of the file is not adjusted for this. Current denominator: July 2023. Description of the variables: Version: Version number of the dataset. When the content of the dataset is structurally changed (so not the daily update or a correction at record level), the version number will be adjusted (+1) and also the corresponding metadata in RIVM data (data.rivm.nl). Version 2 update (May 24, 2022): - Persons who have died or emigrated are removed from the counter. - The denominator data has been updated from December 2021 to April 6, 2022. Version 3 update (July 6, 2022): - The denominator data has been updated from April 6, 2022 to July 6, 2022. - The calculation of the 12 plus population has been adjusted from 2021 – year of birth to 2022 – year of birth. Version 4 update (August 17, 2022): - The booster vaccination rate of the first booster has been added for all birth years. - For [Birth_year] "<=1962" the repeat vaccination rate has been added. Version 5 update (November 29, 2022): - The vaccination rate of the repeat shot against corona within the autumn round of 2022 has been added. This round started on September 19, 2022. -The booster vaccination rate and the repeat vaccination rate have been removed because the data quality of these vaccination rounds is insufficient from the autumn round on September 19, 2022. Version 6 update (4 July 2023): - The calculation of the 12 plus population has been adjusted from 2022 – year of birth to 2023 – year of birth. A more recent denominator has also been used to calculate vaccination attendance and vaccination coverage. - Improvements have been made in the assignment of the ranking number of the vaccinations. This results in some shifts in the data. Date_of_report: Date and time on which the data file was created by RIVM. Date_of_statistics: Start date of the week in which the COVID-19 vaccination was administered, cumulative per calendar week from the start of the vaccination campaign on 06-01-2021. Region_level: Region level to be reported on. This dataset contains data at district level. Region_code: Neighborhood code: neighborhood classification based on the four-digit postal code of the patient's place of residence, coded according to CBS. Region_name: Name of the district. Population: Population figures come from the Personal Data Base Register in CIMS, date: July 2023. ID_Coupling Code: The coupling code indicates which districts have been merged with each other. If one district in a municipality needs to be censored, then this has been merged with a neighboring district, so that the columns population, 'Coverage_primary_partly', 'Coverage_primary_completed' and 'Coverage_repeat_vaccination_autumn_round' of both districts have been merged. Population_merged: Combined population numbers of neighborhoods with the same ID_match code. Based on this column, Coverage_primary_partly (vaccination attendance) are Coverage_primary_completed (vaccination rate basic series), 'Coverage_repeat_vaccination_autumn_round' (vaccination rate repeat vaccination within the autumn round) calculated. Coverage_primary_partly: Cumulative vaccination coverage by district, based on the cumulative number of people who received at least one dose of COVID-19 vaccine, divided by the number of residents. Vaccination attendance is based on data from CIMS. At the moment that traceability could possibly arise based on the population numbers, 9999 will be displayed. This is only the case if at least two neighborhoods within a municipality have 60 inhabitants or less. Coverage_primary_completed: Vaccination rate basic series by district, based on the cumulative number of people who have completed the basic vaccination series, divided by the number of inhabitants. The vaccination rate is based on data from CIMS. Primary completed is defined as receipt of the recommended number of doses of vaccine for the basic series. For vaccines registered with a primary series vaccination schedule of only one dose, such as the Janssen vaccine, the vaccinated person is counted in “Primary_completed”. At the moment that traceability could possibly arise based on the population numbers, 9999 is displayed (censorship). This is only the case if at least two neighborhoods within a municipality have 60 inhabitants or less. 'Coverage_repeat_vaccination_autumn_round': Cumulative vaccination rate repeat vaccination within the autumn round by district, based on the cumulative number of people who received a repeat vaccination against corona (basic series+1, basic series+2 or basic series+3 vaccination) from September 19, 2022. The vaccination coverage is based on data from CIMS. At the moment that traceability could possibly arise based on the population numbers, 9999 will be displayed. This is only the case if at least two neighborhoods within a municipality have 60 inhabitants or less. The vaccination attendance and vaccination rate are also visualized in maps in the nationwide vaccination PDF. This PDF can be found at: https://www.rivm.nl/covid-19-vaccinatie/numerals-vaccinatieprogramma. Until March 21, 2023, this PDF was published weekly and from April 12, 2023 every four weeks. Every four weeks, a dataset is also posted on data.rivm.nl showing attendance for at least one COVID-19 vaccination and vaccination rate for a completed basic series of COVID-19 vaccination by municipality and safety region per birth cohort (https://data.rivm.nl/ meta/srv/eng/catalog.search#/metadata/205d0bf4-b645-4e5b-84bc-f8ec482fd3f3). The dataset by district has a different data source for the counter, compared to the dataset by municipality and safety region. Only CIMS data can be used for the counter in the dataset by district, because vaccinations carried out by the GGDs (data from the GGD GHOR Nederland from CoronIT) are not specified by district for RIVM. Due to improvements in source data and automation processes, corrections can be made compared to previous publications. -------------------------------------------------- --------------------------------------------- COVID-19 attendance and vaccination coverage for basic series and vaccination coverage for repeat vaccination against corona within the autumn round of 2022, per neighborhood per week This file contains: - The cumulative attendance for at least one COVID-19 vaccination and COVID-19 vaccination coverage for the basic series for persons aged 12 years and older (from 4 January 2021) and the cumulative vaccination coverage for the repeat vaccination against corona within the autumn round of 2022 for persons aged 12 years and older (from 19 September 2022) by neighborhood, by calendar week, by birth cohort. The file is structured as follows: - A set of records per neighborhood. When the attendance or vaccination coverage is less than or equal to 5% or greater than or equal to 95%, these are shown as “<=5” or “>=95” respectively due to possible traceability. When less than 60 people live in more than one neighborhood in a municipality, the number of vaccinations in that neighborhood are not shown due to possible traceability and 9999 is displayed (censorship). If one neighborhood in a municipality has to be censored due to low population numbers, then it has been merged with an adjacent neighborhood based on ID-matching code, so that the columns population, 'Coverage_primary_partly','Coverage_primary_completed' and 'Coverage_repeat_vaccination_autumn_round' of both neighborhoods have been merged. Based on these numbers, the vaccination attendance and vaccination coverage were calculated per neighborhood (per neighborhood denominator data Population_merged). This file is updated every four weeks on a Tuesday with data from the previous four weeks up to and including the last Sunday before the update. Origin of the data: Numerator: Vaccinations registered in CIMS

Morbidity and mortality attributable to COVID-19 is devastating global health systems and economies. Bacillus Calmette Guérin (BCG) vaccination has been in use for many decades to prevent severe forms of tuberculosis in children. Studies have also shown a combination of improved long-term innate or trained immunity (through epigenetic reprogramming of myeloid cells) and adaptive responses after BCG vaccination, which leads to non-specific protective effects in adults. Observational studies have shown that countries with routine BCG vaccination programs have significantly less reported cases and deaths of COVID-19, but such studies are prone to significant bias and need confirmation. To date, in the absence of direct evidence, WHO does not recommend BCG for the prevention of COVID-19. This project aims to investigate in a timely manner whether and why BCG-revaccination can reduce infection rate and/or disease severity in health care workers during the SARS-CoV-2 outbreak in South Africa. These objectives will be achieved with a blinded, randomised controlled trial of BCG revaccination versus placebo in exposed front-line staff in hospitals in Cape Town. Observations will include the rate of infection with COVID-19 as well as the occurrence of mild, moderate or severe ambulatory respiratory tract infections, hospitalisation, need for oxygen, mechanical ventilation or death. HIV-positive individuals will be excluded. Safety of the vaccines will be monitored. A secondary endpoint is the occurrence of latent or active tuberculosis. Initial sample size and follow-up duration is at least 500 workers and 52 weeks. Statistical analysis will be model-based and ongoing in real time with frequent interim analyses and optional increases of both sample size or observation time, based on the unforeseeable trajectory of the South African COVID-19 epidemic, available funds and recommendations of an independent data and safety monitoring board. The study will be supported by a novel 3D lung organoid model of SARS-CoV-2 infection system that can mimic the cascade of immunological events after SARS-CoV-2 infection to determine and analyse the contribution of cellular components to the impact of BCG revaccination in this study. Given the immediate threat of the SARS-CoV-2 epidemic the trial has been designed as a pragmatic study with highly feasible endpoints that can be continuously measured. This allows for the most rapid identification of a beneficial outcome that would lead to immediate dissemination of the results, vaccination of the control group and outreach to the health authorities to consider BCG vaccination for all qualifying health care workers. Methods This dataset was collected in a clinical randomised control trial under the TASK008-BCG CORONA protocol. The trial was conducted in South Africa. This trial was registered with ClinicalTrials.gov, NCT04379336.

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

This archived public use dataset has 11 data elements reflecting United States COVID-19 community levels for all available counties.

The COVID-19 community levels were developed using a combination of three metrics — new COVID-19 admissions per 100,000 population in the past 7 days, the percent of staffed inpatient beds occupied by COVID-19 patients, and total new COVID-19 cases per 100,000 population in the past 7 days. The COVID-19 community level was determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days. New COVID-19 admissions and the percent of staffed inpatient beds occupied represent the current potential for strain on the health system. Data on new cases acts as an early warning indicator of potential increases in health system strain in the event of a COVID-19 surge.

Using these data, the COVID-19 community level was classified as low, medium, or high.

COVID-19 Community Levels were used to help communities and individuals make decisions based on their local context and their unique needs. Community vaccination coverage and other local information, like early alerts from surveillance, such as through wastewater or the number of emergency department visits for COVID-19, when available, can also inform decision making for health officials and individuals.

For the most accurate and up-to-date data for any county or state, visit the relevant health department website. COVID Data Tracker may display data that differ from state and local websites. This can be due to differences in how data were collected, how metrics were calculated, or the timing of web updates.

Archived Data Notes:

This dataset was renamed from "United States COVID-19 Community Levels by County as Originally Posted" to "United States COVID-19 Community Levels by County" on March 31, 2022.

March 31, 2022: Column name for county population was changed to “county_population”. No change was made to the data points previous released.

March 31, 2022: New column, “health_service_area_population”, was added to the dataset to denote the total population in the designated Health Service Area based on 2019 Census estimate.

March 31, 2022: FIPS codes for territories American Samoa, Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands were re-formatted to 5-digit numeric for records released on 3/3/2022 to be consistent with other records in the dataset.

March 31, 2022: Changes were made to the text fields in variables “county”, “state”, and “health_service_area” so the formats are consistent across releases.

March 31, 2022: The “%” sign was removed from the text field in column “covid_inpatient_bed_utilization”. No change was made to the data. As indicated in the column description, values in this column represent the percentage of staffed inpatient beds occupied by COVID-19 patients (7-day average).

March 31, 2022: Data values for columns, “county_population”, “health_service_area_number”, and “health_service_area” were backfilled for records released on 2/24/2022. These columns were added since the week of 3/3/2022, thus the values were previously missing for records released the week prior.

April 7, 2022: Updates made to data released on 3/24/2022 for Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands to correct a data mapping error.

April 21, 2022: COVID-19 Community Level (CCL) data released for counties in Nebraska for the week of April 21, 2022 have 3 counties identified in the high category and 37 in the medium category. CDC has been working with state officials t

BackgroundData on allergic reactions after the administration of coronavirus disease (COVID-19) vaccines are limited. Our aim is to analyze reports of allergic reactions after COVID-19 vaccine administration.MethodsThe Vaccine Adverse Event Reporting System database was searched for reported allergic reactions after the administration of any of the COVID-19 vaccines from December 2020 to June 2021. After data mapping, the demographic and clinical characteristics of the reported cases were analyzed. Potential factors associated with anaphylaxis were evaluated using multivariable logistic regression models.ResultsIn total, 14,611 cases were reported. Most cases of allergic reactions comprised women (84.6%) and occurred after the first dose of the vaccine (63.6%). Patients who experienced anaphylaxis were younger (mean age 45.11 ± 5.6 vs. 47.01 ± 6.3 years, P < 0.001) and had a higher prevalence of a history of allergies, allergic rhinitis, asthma, and anaphylaxis than those who did not (P < 0.05). A history of allergies (odds ratio (OR) 1.632, 95% confidence interval (CI) 1.467–1.816, P < 0.001), asthma (OR 1.908, 95%CI 1.677–2.172, P < 0.001), and anaphylaxis (OR 7.164, 95%CI 3.504–14.646, P < 0.001) were potential risk factors for anaphylaxis. Among the 8,232 patients with reported outcomes, 16 died.ConclusionsFemale predominance in allergic reaction cases after the receipt of COVID-19 vaccines was observed. Previous histories of allergies, asthma, or anaphylaxis were risk factors for anaphylaxis post-vaccination. People with these risk factors should be monitored more strictly after COVID-19 vaccination.

Regarding all Vaccination Data The date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination.

See this link for more information https://imap.maryland.gov/pages/covid-data

Summary The cumulative number of COVID-19 vaccinations percent age group population: 16-17; 18-49; 50-64; 65 Plus.

Description COVID-19 - Vaccination Percent Age Group Population data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet.

COVID-19 is a disease caused by a respiratory virus first identified in Wuhan, Hubei Province, China in December 2019. COVID-19 is a new virus that hasn't caused illness in humans before. Worldwide, COVID-19 has resulted in thousands of infections, causing illness and in some cases death. Cases have spread to countries throughout the world, with more cases reported daily. The Maryland Department of Health reports daily on COVID-19 cases by county.

Terms of Use The Spatial Data, and the information therein, (collectively the Data) is provided as is without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata. This map is for planning purposes only. MEMA does not guarantee the accuracy of any forecast or predictive elements.